1 month ago
Dr Lal PathLabs shares were trading at Rs 2,234.65, up nearly 5 percent from the previous close. The revised price target implies an upside of 8 percent from March 22 closing
March 26, 2024 / 12:57 PM IST
Dr Lal PathLabs shares have seen a correction of around 14 percent so far in 2024, particularly severe compared to listed peers, according to Kotak Institutional Equities.
Shares of Dr Lal PathLabs jumped over 5 percent on March 26 after the diagnostics services provider received a "double" upgrade from Kotak Institutional Equities.
The brokerage upgraded the stock to "add" from "sell" and raised fair value (FV) to Rs 2,360 from Rs 1,975, largely led by increased growth estimates beyond FY26, as it built in lower competitive intensity.
Kotak conducted a pricing exercise across seven cities, which indicated a further improvement in pricing trends for the diagnostic players.
The brokerage said even as the pricing differential of listed incumbents with online players stays elevated at 2x-2.6x, "an increasingly benign competitive landscape alleviates any major concerns on structural volume growth and margins of Dr Lal PathLabs and Metropolis."
Follow our market blog to catch all the live action
Dr Lal PathLabs shares have corrected around 14 percent, so far, this year, which is particularly severe compared to listed peers, according to Kotak Institutional Equities. The correction has been attributed to the exit of the company's CEO.
However, the brokerage said Dr Lal has an able leadership team in place with Om Manchanda as MD and appointment of Shankha Banerjee as CEO would provide continuity.
There has been increasing pricing sanity in 900 diagnostics over the past year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues, Kotak said.
In comparison to a one-year forward price-to-earnings premium of 20 percent, Dr Lal PathLabs is now trading at a discount to Metropolis Healthcare, analysts said.
Also Read | IndiGo shares fly to record high as brokerages foresee strong growth, raise price targets
At 12:28 pm, Dr Lal PathLabs shares were trading at Rs 2,234.65, up nearly 5 percent from the previous close. The revised price target implies a potential upside of 8 percent from March 22 closing levels.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
